SURGALIGN HOLDINGS INC (SRGA) Fundamental Analysis & Valuation

NASDAQ:SRGA • US86882C2044

Current stock price

0.1829 USD
-0.09 (-32.98%)
At close:
0.1235 USD
-0.06 (-32.48%)
After Hours:

This SRGA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SRGA Profitability Analysis

1.1 Basic Checks

  • In the past year SRGA has reported negative net income.
  • In the past year SRGA has reported a negative cash flow from operations.
SRGA Yearly Net Income VS EBIT VS OCF VS FCFSRGA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

  • SRGA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRGA Yearly ROA, ROE, ROICSRGA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 -400

1.3 Margins

  • The Gross Margin of SRGA (47.06%) is comparable to the rest of the industry.
  • SRGA's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SRGA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.98%
GM growth 5Y-0.73%
SRGA Yearly Profit, Operating, Gross MarginsSRGA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100 -150

2

2. SRGA Health Analysis

2.1 Basic Checks

  • SRGA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SRGA has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, SRGA has a worse debt to assets ratio.
SRGA Yearly Shares OutstandingSRGA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
SRGA Yearly Total Debt VS Total AssetsSRGA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -14.39, we must say that SRGA is in the distress zone and has some risk of bankruptcy.
  • SRGA's Altman-Z score of -14.39 is on the low side compared to the rest of the industry. SRGA is outperformed by 85.51% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.39
ROIC/WACCN/A
WACC5.62%
SRGA Yearly LT Debt VS Equity VS FCFSRGA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 2.67 indicates that SRGA has no problem at all paying its short term obligations.
  • SRGA has a worse Current ratio (2.67) than 60.87% of its industry peers.
  • SRGA has a Quick Ratio of 2.00. This is a normal value and indicates that SRGA is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of SRGA (2.00) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.67
Quick Ratio 2
SRGA Yearly Current Assets VS Current LiabilitesSRGA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2

3. SRGA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 50.34% over the past year.
  • The Revenue for SRGA has decreased by -11.04% in the past year. This is quite bad
  • Measured over the past years, SRGA shows a very negative growth in Revenue. The Revenue has been decreasing by -21.76% on average per year.
EPS 1Y (TTM)50.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)-11.04%
Revenue growth 3Y-11.28%
Revenue growth 5Y-21.76%
Sales Q2Q%-18.72%

3.2 Future

  • SRGA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -26.80% yearly.
  • The Revenue is expected to grow by 5.28% on average over the next years.
EPS Next Y-58.25%
EPS Next 2Y-26.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-37.13%
Revenue Next 2Y-17.44%
Revenue Next 3Y10.86%
Revenue Next 5Y5.28%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SRGA Yearly Revenue VS EstimatesSRGA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
SRGA Yearly EPS VS EstimatesSRGA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

0

4. SRGA Valuation Analysis

4.1 Price/Earnings Ratio

  • SRGA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRGA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRGA Price Earnings VS Forward Price EarningsSRGA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRGA Per share dataSRGA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

  • A cheap valuation may be justified as SRGA's earnings are expected to decrease with -26.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.8%
EPS Next 3YN/A

0

5. SRGA Dividend Analysis

5.1 Amount

  • No dividends for SRGA!.
Industry RankSector Rank
Dividend Yield N/A

SRGA Fundamentals: All Metrics, Ratios and Statistics

SURGALIGN HOLDINGS INC

NASDAQ:SRGA (6/30/2023, 8:00:01 PM)

After market: 0.1235 -0.06 (-32.48%)

0.1829

-0.09 (-32.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-11
Earnings (Next)08-07
Inst Owners0%
Inst Owner Change0%
Ins Owners110.88%
Ins Owner Change0%
Market Cap1.68M
Revenue(TTM)78.12M
Net Income(TTM)-50.49M
Analysts82
Price Target2.3 (1157.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.19%
Min EPS beat(2)34.2%
Max EPS beat(2)62.17%
EPS beat(4)4
Avg EPS beat(4)31.3%
Min EPS beat(4)12.05%
Max EPS beat(4)62.17%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)6.19%
Min Revenue beat(2)-3.37%
Max Revenue beat(2)15.74%
Revenue beat(4)1
Avg Revenue beat(4)0.19%
Min Revenue beat(4)-7.31%
Max Revenue beat(4)15.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.18%
EPS NQ rev (1m)-0.98%
EPS NQ rev (3m)36.11%
EPS NY rev (1m)-0.98%
EPS NY rev (3m)-47.17%
Revenue NQ rev (1m)0.98%
Revenue NQ rev (3m)-16.92%
Revenue NY rev (1m)0.98%
Revenue NY rev (3m)-37.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.81
EYN/A
EPS(NY)-11.27
Fwd EYN/A
FCF(TTM)-5.36
FCFYN/A
OCF(TTM)-4.57
OCFYN/A
SpS8.51
BVpS-0.97
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.06%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.98%
GM growth 5Y-0.73%
F-Score2
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 341.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.67
Quick Ratio 2
Altman-Z -14.39
F-Score2
WACC5.62%
ROIC/WACCN/A
Cap/Depr(3y)371.14%
Cap/Depr(5y)257.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y-58.25%
EPS Next 2Y-26.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.04%
Revenue growth 3Y-11.28%
Revenue growth 5Y-21.76%
Sales Q2Q%-18.72%
Revenue Next Year-37.13%
Revenue Next 2Y-17.44%
Revenue Next 3Y10.86%
Revenue Next 5Y5.28%
EBIT growth 1Y-18.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.51%
OCF growth 3YN/A
OCF growth 5YN/A

SURGALIGN HOLDINGS INC / SRGA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SURGALIGN HOLDINGS INC (SRGA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to SRGA.


What is the valuation status of SURGALIGN HOLDINGS INC (SRGA) stock?

ChartMill assigns a valuation rating of 0 / 10 to SURGALIGN HOLDINGS INC (SRGA). This can be considered as Overvalued.


Can you provide the profitability details for SURGALIGN HOLDINGS INC?

SURGALIGN HOLDINGS INC (SRGA) has a profitability rating of 0 / 10.


Can you provide the financial health for SRGA stock?

The financial health rating of SURGALIGN HOLDINGS INC (SRGA) is 1 / 10.